



**ASX ANNOUNCEMENT**

**5 April 2019**

## **Addendum to Annual Report**

Medical technology company, **HeraMED Limited (ASX:HMD)** ("HeraMED" or the "Company") advises that the Annual Report for the period ending 31 December 2018, which was lodged by way of an announcement on the ASX platform on 29 March 2019, contained an error.

The error relates to the number of options in which both David Groberman and Tal Slonim hold a relevant interest. The Annual Report notes that they each hold a relevant interest in 3,750,000 Unlisted Options ("Unlisted Director Options") expiring 5 December 2021 exercisable at \$0.25, escrowed until 12 December 2020.

The correct position is that they each hold a relevant interest in 3,187,500 Unlisted Options ("Unlisted Director Options") expiring 5 December 2021 exercisable at \$0.25, escrowed until 12 December 2020.

This error does not affect the financial results of the Company as reported in the Annual Report.

**-ENDS-**

HeraMED Limited

CEO and Co-Founder

David Groberman

M:+972-52-6991188

E: David@hera-med.com

Company Secretary

Stephen Buckley

T: +61 (0)8 6189 1155

E: stephen@companysecsol.com.au

### **About HeraMED Limited (ASX:HMD):**

HeraMED Limited is an innovative medical technology company delivering smart pregnancy monitoring solutions for home and professional use. HeraMED provides peace of mind to expecting parents by solving problems associated with the reliability of pre-natal analysis, as well as the cost and shortage in fundamental services through end-to-end medical grade solutions utilising monitoring devices, cloud based platforms and AI capabilities.

HeraMED is commercialising the worlds most advanced, smart medical grade ultrasound monitoring device HeraBEAT. The device has passed multiple clinical trials and secured approval by key regulatory bodies including TGA (Australia), CE (Europe) and AMAR (Israel) for commercial sale.

The Company has partnerships with two leading medical organisations, the Mayo Clinic and TEVA Pharmaceutical Industries Inc. (NYSE: TEVA). HeraMED diversifying its product range and services with the launch of SaaS services and cloud based monitoring systems.